NPPB and heart failure: A post hoc analysis showed that this effect on eGFR was consistent across baseline UACR and eGFR subgroups and that the absolute risk reduction was highest in the lowest eGFR and highest albuminuria categories, with no difference in the risk of heart failure hospitalization across these subgroups, and that risk for heart failure was associated with baseline BNP and early changes of BNP in response to atrasentan [27, 28].